New drug duo targets Hard-to-Treat lymphoma
NCT ID NCT05672251
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 4 times
Summary
This phase 2 trial tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can shrink tumors in people with diffuse large B-cell lymphoma that has relapsed or become resistant. The study will enroll 36 adults and measure how many patients respond and what side effects occur. Both drugs work by helping the immune system attack cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- loncastuximab tesirine and mosunetuzumab
- What this could lead to
- If this combination works, it could offer a new treatment option for people with aggressive B-cell lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- This is a small, early-phase trial (36 people) with no control group, so results may not apply broadly. The drugs can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- Engineered immune cells take on tough blood cancers in early trial
- New combo therapy aims to stop aggressive lymphoma relapse
- New combo approach aims to boost CAR-T success in tough lymphoma